MA44110B1 - Polythérapie - Google Patents
PolythérapieInfo
- Publication number
- MA44110B1 MA44110B1 MA44110A MA44110A MA44110B1 MA 44110 B1 MA44110 B1 MA 44110B1 MA 44110 A MA44110 A MA 44110A MA 44110 A MA44110 A MA 44110A MA 44110 B1 MA44110 B1 MA 44110B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- alaninyl
- benzoxy
- combination therapy
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne une association de gemcitabine- [phényl-benzoxy-l-alaninyl)]-phosphate (nom chimique: 2 '-désoxy -2 ', 2 '-difluoro-d-cytidine -5 '-o- [phényl (benzoxy-l-alaninyl) ] phosphate) (nuc -1031) et un agent anticancéreux à base de platine choisi parmi le cisplatine, le picoplatine, le lipoplatine et le triplatine. Les combinaisons sont utiles dans le traitement du cancer et en particulier le cancer de la vésicule et des voies biliaires et le cancer de la vessie.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2015/054158 WO2017109444A1 (fr) | 2015-12-23 | 2015-12-23 | Traitement combiné |
PCT/GB2016/054018 WO2017109486A1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
EP16820005.3A EP3393478B1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44110A MA44110A (fr) | 2018-10-31 |
MA44110B1 true MA44110B1 (fr) | 2020-03-31 |
Family
ID=55069010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44110A MA44110B1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190381084A1 (fr) |
KR (1) | KR102566461B1 (fr) |
AU (1) | AU2015418015B2 (fr) |
CA (1) | CA3008769A1 (fr) |
MA (1) | MA44110B1 (fr) |
WO (1) | WO2017109444A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033335T2 (en) | 2012-11-16 | 2017-11-28 | Univ College Cardiff Consultants Ltd | RP / SP gemcitabine [phenyl (benzyloxy-L-alaninyl)] phosphate mixture |
MY186584A (en) | 2014-06-25 | 2021-07-28 | Nucana Biomed Ltd | Formulation comprising a gemcitabine-prodrug |
ES2948660T3 (es) | 2014-06-25 | 2023-09-15 | NuCana plc | Profármacos de gemcitabina |
GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
KR20180063075A (ko) | 2015-10-05 | 2018-06-11 | 뉴카나 피엘씨 | 조합 요법 |
SG11201804774YA (en) | 2015-12-11 | 2018-07-30 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
TWI787201B (zh) | 2016-08-31 | 2022-12-21 | 日商富士軟片股份有限公司 | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 |
GB201713914D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Combination therapy |
AU2021373619A1 (en) * | 2020-11-03 | 2023-06-15 | Cornerstone Pharmaceuticals, Inc. | Therapeutic methods and compositions for treating biliary tract cancer using devimistat |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
EA201792509A1 (ru) * | 2015-05-14 | 2018-05-31 | НУКАНА ПиЭлСи | Лечение рака |
-
2015
- 2015-12-23 KR KR1020187020532A patent/KR102566461B1/ko active IP Right Grant
- 2015-12-23 AU AU2015418015A patent/AU2015418015B2/en not_active Ceased
- 2015-12-23 WO PCT/GB2015/054158 patent/WO2017109444A1/fr active Application Filing
- 2015-12-23 CA CA3008769A patent/CA3008769A1/fr active Pending
- 2015-12-23 US US16/065,476 patent/US20190381084A1/en not_active Abandoned
-
2016
- 2016-12-21 MA MA44110A patent/MA44110B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR102566461B1 (ko) | 2023-08-14 |
AU2015418015B2 (en) | 2021-12-09 |
CA3008769A1 (fr) | 2017-06-29 |
AU2015418015A1 (en) | 2018-07-05 |
WO2017109444A1 (fr) | 2017-06-29 |
KR20180096697A (ko) | 2018-08-29 |
MA44110A (fr) | 2018-10-31 |
US20190381084A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44110B1 (fr) | Polythérapie | |
PH12018501339A1 (en) | Combination therapy | |
PH12018500691A1 (en) | Combination therapy | |
MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
PH12014501106A1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
EA200970891A1 (ru) | Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы | |
PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
WO2008120098A3 (fr) | Promédicaments peptidiques | |
MX2017013074A (es) | Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
WO2007124314A3 (fr) | Utilisation de transporteurs de cations organiques pour le diagnostic et le traitement du cancer | |
MA43294A1 (fr) | Sels et promédicaments de 1-méthyl -d-tryptophane | |
MX2018012545A (es) | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. | |
IN2014DN04596A (fr) | ||
MX2019008919A (es) | Moduladores de rorgamma y usos de los mismos. | |
MX2019006685A (es) | Combinacion terapeutica para el tratamiento de cancer. | |
WO2023097197A3 (fr) | Compositions et méthodes pour évaluer l'efficacité d'une administration de polynucléotides et d'une thérapie anticancéreuse | |
Spry et al. | Resistance Training and Cancer Survival/In Reply |